More on Cerus (CERS): Q1 misses across the board, despite a 12% Y/Y increase total sales. Gross...

|About: Cerus Corporation (CERS)|By:, SA News Editor

More on Cerus (CERS): Q1 misses across the board, despite a 12% Y/Y increase total sales. Gross margins jumped to 48% from 37%, driven primarily by lower product costs on improved overhead and higher manufacturing levels during H212. This wasn't enough to offset an increase in operating expenses however, due largely to regulatory activities for the submission of its INTERCEPT platelet and plasma modular PMA applications in the U.S. Operating losses were $5M, compared to $4.6M the previous year. Read more on earnings here: Earnings Call Transcript.